Data identified both clinical and employment factors that may predict poor work outcomes in patients with axial spondyloarthritis.
Higher radiographic progression was associated with increased inflammation and damage in early axial spondyloarthritis.
Results do not suggest that separate diagnostic strategies for men and women are required.
Results suggest that C-reactive protein testing should be repeated after at least 4 weeks.
Findings suggest that repeating MRI of the sacroiliac joints after 3 months or 1 year in patients with chronic back pain and suspected axial spondyloarthritis was not useful.
Patients with axial spondyloarthritis who have inflammatory back pain or neuropathic pain may have higher pain intensity, pain interference, disease activity, and greater functional limitation compared with individuals with axial spondyloarthritis but without either comorbidity.
Patients who reported a greater symptom burden at the start of TNFi treatment had poor response rates and low retention rates.
VIBE detected erosions in the sacroiliac joints with higher sensitivity without a loss of specificity and superior reliability compared with a standard T1-weighted sequence.
The location and spread of pain in patients with axial spondyloarthritis was different between genders and was related to worse clinical status.
Consistent data show that treatment with biologic therapy significantly improves work productivity and activity impairment among patients with axial spondyloarthritis.
Investigators compared the performance of different spinal radiographic damage scoring methods in patients with early axial spondyloarthritis.
Meeting the criteria for fibromyalgia had a modest effect on disease activity and did not influence the response to TNFi therapy.
Depression is common in patients with axSpA and is associated with more severe disease activity and functional impairment.
Researchers sought to assess whether it is possible to discriminate between degenerative changes and lesions associated with axSpA.
In patients with nonradiographic axial spondyloarthritis who achieve remission with adalimumab, continued therapy was linked to fewer flares vs treatment withdrawal.
Researchers assessed the reproducibility of UCOASMI in clinical practice settings.
An improved understanding of the gender differences in axial spondyloarthritis can improve disease treatment and reduce disease burden.
The Assessment of Spondyloarthritis International Society Health Index proved to be valid, reliable, and responsive.
A systematic review revealed no signal for increased pregnancy loss in patients with axial spondyloarthritis.
Researchers sought to evaluate the efficacy, tolerability, and persistence of TNFi and ustekinumab in patients with psoriatic arthritis initiating first-line, second-line, or third-line biologic DMARDs.
Increased interleukin-31 levels may protect against structural damage in patients with axial spondyloarthritis.
Axial spondyloarthritis disease duration was associated with higher risk of developing acute anterior uveitis and inflammatory bowel disease, but not psoriasis.
Hidradenitis suppurativa is more common in patients with axial spondyloarthritis compared with the general population.
Certolizumab Pegol Demonstrates Positive Results in Phase 3 Trial for Nonradiographic Axial SpondyloarthritisMay 17, 2018
Results from a phase 3 trial show that certolizumab pegol improves the signs and symptoms of nonradiographic axial spondyloarthritis compared with placebo at 52 weeks.
The incidence of adverse cardiovascular events in patients with RA do not differ significantly compared with those with PsA or axSpA.
Researchers sought to investigate the utility of adding structural MRI lesions of the sacroiliac joints to the imaging criterion of the ASAS axSpA criteria.
Results from the ABILITY-1 study show sustained clinical and functional improvements with adalimumab treatment in nonradiographic axial spondyloarthritis.
Researchers found that disease activity was highest during the second trimester of pregnancy.
Researchers found that trabecular bone scores may be predictive of future vertebral fractures in patients with axial spondyloarthritis.
Researchers sought to confirm whether concomitant fibromyalgia has a negative effect on TNF blocker response.
Rheumatology Advisor Articles
- 5-Step Guide to Activity Tracker Use for Patients With Rheumatic Diseases
- Gout Associated With Worse Outcomes in Obstructive Coronary Artery Disease
- Filgotinib Effective for Treatment of Active Psoriatic Arthritis
- Standard Set of Outcomes Developed for Value-Based Health Care in Inflammatory Arthritis
- Clinically Meaningful Improvement in Rheumatoid Arthritis Assessed With RAPID-3
- Circadian Rhythm in Rheumatoid Arthritis: Using Chronotherapy to Improve Outcomes
- Transcutaneous Electrical Nerve Stimulation Reduces Pain, Fatigue in Fibromyalgia
- Aspirin, Anticoagulants Similarly Prevent VTE After TKA
- Study: Cold Weather Joint Pain and Other Weather-Related Pain
- Increased Opioid Prescribing Linked to Chronic Usage in Patients With RA
- Assessing Insurance Coverage Trends in Lesbian, Gay, and Bisexual Adults in the Post-ACA Era
- Immunogenicity of Pneumococcal Vaccines Examined in Children With SLE
- Decreased Health, Social Service Utilization Among Immigrants Following 2016 Presidential Election
- Making the Case for Donor-Funded Research
- Positive Coombs Test Without Hemolytic Anemia Predicts Disease Activity in SLE